Notice2024-07941
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Rapid Response Partnership Vehicle
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 16, 2024
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 74 (Tuesday, April 16, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Pages 26928-26929]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-07941]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Rapid Response Partnership Vehicle
Notice is hereby given that, on January 5, 2024, pursuant to
section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership
Vehicle (``RRPV'') has filed written notifications simultaneously with
the Attorney General and the Federal Trade Commission disclosing (1)
the identities of the parties to the venture and (2) the nature and
objectives of the venture. The notifications were filed for the purpose
of invoking the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Pursuant to section 6(b) of the Act, the identities of the parties
to the venture as of the date of this filing are: AATec Medical GmbH,
M[uuml]nchen, GERMANY; ASELL LLC, Owings Mills, MD; Access to Advanced
Health Institute, Seattle, WA; Adaptive Phage Therapeutics, Inc.,
Gaithersburg, MD; Advanced BioScience Laboratories, Inc., Rockville,
MD; Aerium Therapeutics, Inc., Boston, MA; Alamgir Research, Inc. dba
ARIScience, Wayland, MA; Alchem Laboratories Corp., Alachua, FL;
Alentic Microscience, Inc., Halifax, Nova Scotia, CANADA; Altec, Inc.,
Natick, MA; Antiviral Technologies LLC, Dallas, TX; ApiJect Systems
America, Inc., Stamford, CT; Applied Materials, Inc., Santa Clara, CA;
Apriori Bio, Inc., Cambridge, MA; Aridis Pharmaceuticals, Inc., Los
Gatos, CA; AstraZeneca Pharmaceuticals LP, Wilmington, DE; Atea
Pharmaceuticals, Inc., Boston, MA; Attogene, Austin, TX; BCG Federal
Corp., Washington, DC; BioFire Defense LLC, Salt Lake City, UT;
BioTechnique LLC, York, PA; BiotechPharma Corp., Severna Park, MD;
Bioxytran, Dedham, MA; Boston Engineering Corp., Waltham, MA;
BrainScope Company, Inc., Chevy Chase, MD; Brimrose Technology
Corporation, Sparks, MD; BugSeq, Inc., San Francisco, CA; CAMRIS
International, Bethesda, MD; CASTLEVAX, Inc., New York, NY; CUBRC,
Inc., Buffalo, NY; Care Access Research LLC, Boston, MA; Cayuga
Biotech, New York, NY; Cepheid, Sunnyvale, CA; ChromoLogic, Monrovia,
CA; Civica, Inc., Lehi, UT; Clarivate Analytics (US) LLC, Ann Arbor,
MI; CliniOps, Inc., Fremont, CA; Cocrystal Pharma, Inc., Miami, FL;
Codagenix, Inc., Farmingdale, NY; Concord Medical Technology Corp.,
Grand Forks, ND; Critical Innovations LLC, Lawndale, CA; Curia Global,
Inc., Albany, NY; CyanVac LLC, Athens, GA; Delta Development Team,
Inc., Tucson, AZ; Detect, Inc., Guilford, CT; Duke University, Durham,
NC; Dyadic International, Inc., Jupiter, FL; Dynavax Technologies
Corp., Emeryville, CA; Eagle Health Analytics LLC, San Antonio, TX;
Endpoint Health, Palo Alto, CA; Esparza Pest Control and Eco-Logic
Systems, Inc., Edinburg, TX; EverGlade Consulting LLC, Charleston, SC;
Everest Consulting Group, Bethesda, MD; ExeVir Bio, Zwijnaarde,
BELGIUM; FHI Clinical, Durham, NC; First Line Technology LLC,
Fredericksburg, VA; Foamtec International Co., Ltd., Waco, TX; Foothill
Scientific Associates, CA; GRIP Molecular Technologies, Inc., St. Paul,
MN; GenVault, West Deptford, NJ; Generate Biomedicines, Inc.,
Somerville, MA; GeoVax, Inc., Smyrna, GA; Ginkgo Bioworks, Inc.,
Boston, MA; Global Resonance Technologies LLC, Shelburne, VT; Gritstone
bio, Inc., Emeryville, CA; Healthtrek LLC, Tampa, FL; Hexagon Bio,
Inc., Menlo Park, CA; ICON Government and Public Health Solutions,
Inc., Blue Bell, PA; Immune Biosolutions, Sherbrooke, CANADA;
ImmunityBio, Inc., Culver City, MN; Immuron, Ltd., Blackburn North,
AUSTRALIA; Inflammatix, Inc., Sunnyvale, CA; Integrated Pharma
Services, Frederick, MD; Invivyd, Inc., Waltham, MA; Irving Burton
Associates LLC, Silver Spring, MD; Island Pharmaceuticals, Ltd.,
Camberwell, AUSTRALIA; Iuventis Technologies, Inc., Olean, NY; JEEVA
INFORMATICS
[[Page 26929]]
SOLUTIONS, Inc., Manassas, VA; Jubilant HollisterStier, Spokane, WA;
Jurata Thin Film, Inc., Houston, TX; K2 Biolabs, Inc., Houston, TX;
LaCire LLC, Alexandria, VA; Latham BioPharm Group LLC, Elkridge, MD;
Leidos, Reston, VA; Lex Diagnostics, Ltd., Melbourn, UNITED KINGDOM;
Locus Biosciences, Morrisville, NC; Longhorn Vaccines and Diagnostics
LLC, Bethesda, MD; Luna Labs USA LLC, Charlottesville, VA; Lungpacer
Medical USA, Inc., Exton, PA; MMV Medicines for Malaria Venture,
Geneva, SWITZERLAND; MRIGlobal, Gaithersburg, MD; Mapp
Biopharmaceutical, Inc., San Diego, CA; Maravai Lifesciences, San
Diego, CA; Maxwell Biosciences, Inc., Austin, TX; MeMed, Tirat Carmel,
ISRAEL; Medigen, Inc, Frederick, MD; Meletios Therapeutics, Paris,
FRANCE; Micron Biomedical, Inc., Atlanta, GA; Military Health Research
Foundation, Inc., Laurel, MD; Mission Pharmacal Company, San Antonio,
TX; Model Medicines, Inc., La Jolla, CA; ModernaTx, Cambridge, MA;
Molecular Technologies Laboratories LLC dba InfinixBio, Galena, OH;
NextBeam LLC, North Sioux City, SD; Ocugen, Inc., Malvern, PA; Ocyonbio
LLC, Aguadilla, PUERTO RICO; OneBreath, Inc., Palo Alto, CA; Otter Cove
Solutions LLC, Gaithersburg, MD; PPD Development LP, Wilmington, NC;
Pacto Medical, Inc., Middletown, DE; Parallel Biosciences, Inc.,
Cambridge, MA; Peptilogics, Inc., Pittsburgh, PA; Pfizer, Inc., New
York, NY; Phare Bio, Boston, MA; Pharm-Olam LLC dba Allucent, Cary, NC;
PharmaJet, Inc., Golden, CO; Phlow Corp., Richmond, VA; PopVax Private
Limited, Mumbai City, INDIA; QUZE Pharmaceuticals, Inc., Windsor, CO;
Rajant Health, Inc., Malvern, PA; Regis Technologies, Inc., Morton
Grove, IL; Research Lifecycle Solutions LLC, Franklin, TN; Resilience
Government Services, Inc., Alachua, FL; Riya Interactive Inc., Hawthorn
Woods, IL; Ronawk, Inc., Overland Park, KS; Rubix Strategies LLC dba
Rubix LS, Lawrence, MA; SEQENS, Devens, MA; SRI International, Menlo
Park, CA; Safi Biotherapeutics, Inc., Cambridge, MA; Sanofi Pasteur,
Inc., Swiftwater, PA; Schrodinger LLC, Portland, OR; Shabas Solutions
LLC, Fairfax, VA; Sibel Health, Inc., Chicago, IL; Signature Science
LLC, Austin, TX; Swaza Inc., Mountain View, CA; Synedgen, Inc.,
Claremont, CA; TFF Pharmaceuticals, Inc., Fort Worth, TX; Texas
Biomedical Research Institute, San Antonio, TX; The Conafay Group,
Washington, DC; The Geneva Foundation, Tacoma, WA; The Henry M. Jackson
Foundation for the Advancement of Military Medicine, Bethesda, MD; The
Medical Countermeasures Coalition, Washington, DC; The Tiny Cargo
Company, Roanoke, VA; ThirdLaw Molecular LLC, Blue Bell, PA; TrippBio,
Inc., Jacksonville, FL; Uh-Oh Labs Inc. dba Scout, Santa Clara, CA;
Univox Technical Solutions DBA Univox LLC, Tijeras, NM; Valneva Austria
GmbH, Vienna, AUSTRIA; Vanderbilt Vaccine Center, Nashville, TN; Varda
Space Industries, Inc., El Segundo, CA; Vaxart, Inc., South San
Francisco, CA; Vaxess Technologies, Inc., Cambridge, MA; Vaxxas, Inc.,
Cambridge, MA; Vibrent Health, Fairfax, VA; Vir Biotechnologies, San
Francisco, CA; Viti Pharmaceuticals, Miami, FL; Wizbiosolutions, Inc.,
Vienna, VA.
Consistent with 15 U.S.C. 4301(a)(6)(C), (E) and (F), the general
area of RRPV's planned activities are to accelerate Medical
Countermeasure (MCM) technology development to address evolving needs
including pandemic influenza, emerging infectious diseases, and other
biological threats. It will accelerate partnering, improve
responsiveness, and meet expanding demand to develop future MCM needs.
It will advance health security, enhance preparedness, and enable a
rapid response to future pandemic or high consequence biological
threats.
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-07941 Filed 4-15-24; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on April 16, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.